



Review

Non-Malignant Central Airway Obstruction[☆]

David Barros Casas,^{a,b} Sebastian Fernández-Bussy,^c Erik Folch,^d Javier Flandes Aldeyturriaga,^b Adnan Majid^{d,*}



^a Servicio de Neumología, Hospital Universitario La Paz, Madrid, Spain

^b Unidad de broncoscopia, Servicio de Neumología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

^c Servicio de Neumología Intervencionista, Clínica Alemana-Universidad del Desarrollo de Chile, Santiago de Chile, Chile

^d Division of Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, United States

ARTICLE INFO

Article history:

Received 20 June 2013

Accepted 28 December 2013

Available online 2 July 2014

Keywords:

Non-malignant airway obstruction

Tracheobronchial stenosis

Granulation tissue

Tracheostomy

Diagnostic and therapeutic bronchoscopy

Intubation

ABSTRACT

The most common causes of non-malignant central airway obstruction are post-intubation and post-tracheostomy/tracheal stenosis, followed by the presence of foreign bodies, benign endobronchial tumors and tracheobronchomalacia. Other causes, such as infectious processes or systemic diseases, are less frequent. Despite the existence of numerous classification systems, a consensus has not been reached on the use of any one of them in particular. A better understanding of the pathophysiology of this entity has allowed us to improve diagnosis and treatment. For the correct diagnosis of nonspecific clinical symptoms, pulmonary function tests, radiological studies and, more importantly, bronchoscopy must be performed. Treatment must be multidisciplinary and tailored to each patient, and will require surgery or endoscopic intervention using thermoablative and mechanical techniques.

© 2013 SEPAR. Published by Elsevier España, S.L. All rights reserved.

Patología obstructiva no maligna de la vía aérea central

RESUMEN

Las causas más frecuentes de patología obstructiva no maligna de la vía aérea central son las estenosis postintubación y postraqueotomía, seguidas por los cuerpos extraños y la traqueobroncomalacia. Otras causas, como las secundarias a procesos infecciosos y enfermedades sistémicas, son menos frecuentes. A pesar de la existencia de numerosas clasificaciones, todavía no se ha alcanzado consenso sobre la utilización de alguna de ellas en concreto. Un mejor conocimiento de su fisiopatología nos ha permitido aumentar el diagnóstico y mejorar su tratamiento; su presentación clínica inespecífica exige la realización de diversos estudios funcionales, radiológicos y fundamentalmente endoscópicos para su correcto diagnóstico. El tratamiento debe ser multidisciplinario e individualizado, requiriendo tratamiento quirúrgico o endoscópico mediante diferentes técnicas termoablativas y mecánicas.

© 2013 SEPAR. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Introduction

Obstruction of the central airway, trachea and primary bronchi is a common problem in medical and surgical settings. The incidence of this disorder seems to be rising due to the epidemic of lung cancer; however, the growing number of benign obstructive pathologies also contributes to this trend, primarily due to the use of artificial airways.¹ Multidisciplinary management and progress

in the use of different radiological and endoscopic tools have led to an improvement in the diagnosis and treatment of these conditions.

The aim of this review is to examine the causes of benign central airway obstruction considered most important by the authors, including intubation, tracheotomy, tracheobronchomalacia (TBM), infectious processes (tuberculosis) and systemic diseases (sarcoidosis, amyloidosis, Wegener's granulomatosis, relapsing polychondritis, tracheobronchopathia osteochondroplastica), and finally, idiopathic tracheal stenosis and post-lung transplantation bronchial stenosis.

Etiology and Classification

There are many causes of central airway obstruction (Table 1), the most common being associated with orotracheal intubation

[☆] Please cite this article as: Barros Casas D, Fernandez S, Folch E, Flandes Aldeyturriaga J, Majid A. Patología obstructiva no maligna de la vía aérea central. Arch Bronconeumol. 2014;50:345–354.

* Corresponding author.

E-mail address: amajid@bidmc.harvard.edu (A. Majid).




Figure 1. Images of different types of non-malignant obstructive airway disease. (1) Post-intubation stenosis. (2) Granulation stenosis secondary to silicone stent. (3) Tracheobronchomalacia. (4) Stenosis secondary to Wegener's granulomatosis. (5) Stenosis secondary to tuberculosis. (6) Tracheobronchopathia osteochondroplastica. (7) Idiopathic stenosis. (8) Hamartoma. (9) Solitary papilloma. (10) Papillomatosis.

and tracheotomy. Tracheomalacia is another important cause currently gaining recognition. Other less common causes are chronic inflammatory diseases (amyloidosis, sarcoidosis and relapsing polychondritis), infectious diseases (tuberculosis and rhinoscleroma) and collagen vascular diseases (granulomatosis with polyangiitis or Wegener's granulomatosis and lupus). Lung transplant patients can present symptomatic stenosis or malacia at the site of the anastomosis. Finally, if no other cause is identified, the condition may be termed idiopathic tracheal stenosis.^{2,3} There are other causes of obstruction that will not be addressed in this review, such as extrinsic compression due to cervical lymphadenopathies or masses, obstruction due to benign endoluminal tumors (Fig. 1, images 8–10), radiation and inhalation lesions, and the aspiration of foreign material.

Table 1
Conditions Associated With Non-malignant Airway Obstruction.

Lymphadenopathies
Infectious
Inflammatory diseases
Sarcoidosis
Wegener's granulomatosis
Vascular
Rings
Anatomical variations
Granulation tissue
Endotracheal tubes
Tracheostomy tubes
Airway stents
Foreign material
Surgical anastomosis
Wegener's granulomatosis
Pseudotumor
Hamartomas
Amyloid
Papillomatosis
Hyperdynamic
Tracheobronchomalacia
Excessive pars membranosa collapse
Idiopathic
Tuberculosis
Sarcoidosis
Other
Goiter
Mucous plug
Vocal cords
Epiglottitis
Blood clot

Recently, Freitag et al.⁴ published a classification system aiming to divide stenosis into structural and dynamic types, with additional categorization by degree of stenosis and site. Unfortunately, this classification is complex and has not been universally accepted (Fig. 2).

In the opinion of the authors, the most important differentiation to be made is between simple and complex stenoses, since this determines the success or failure of the endoscopic intervention. A complex stenosis is defined here as stenosis with one or more of the following characteristics: long (>10 mm), tortuous, with contractions or cartilaginous damage associated with malacia. All these factors add to the difficulty of endoscopic intervention and make surgery the therapeutic method of choice.

Clinical Presentation

Varying degrees of dyspnea and cough, stridor and wheezing make up the clinical spectrum of this disorder. Clinical




Figure 2. Stenosis classification system, according to site, grade and type of stenosis, proposed by Freitag et al.⁴

presentation will depend not only on the underlying disease but also on the site of the lesion, the degree of narrowing of the lumen and how fast it progresses. Other factors, such as the patient's underlying state of health, may play an important role in the progress and final outcome of the process. Up to 54% of patients with tracheal stenosis initially present with respiratory distress,⁵ since before symptoms appear, there has been a significant and progressive loss of airway lumen diameter. Due to the similarity of the symptoms and partial response to corticosteroids, bronchodilators and antibiotics, most patients, for varying periods of time, are erroneously diagnosed with difficult-to-control asthma or recurrent chronic bronchitis. Persistent symptoms despite treatment and a strong clinical suspicion should guide the correct diagnosis.

Diagnostic Evaluation

The most commonly used diagnostic studies are pulmonary function tests, computed tomography (CT) and bronchoscopy.⁶

Pulmonary function tests are useful for both diagnosis and follow-up after an intervention. In the case of tracheal stenosis, a trend toward flattening of the inspiratory and expiratory flow-volume loop is observed, depending on the site and characteristics of the lesion.⁷ This change is not normally seen until the tracheal lumen measures less than 10 mm. While variable extrathoracic obstructions show flattening of the inspiratory loop, intrathoracic obstructions show flattening of the expiratory loop. Fixed obstructions show flattening of both loops.

Extremely thin slices allowing 3-dimensional reconstructions that are highly useful for diagnostic purposes can be obtained with the multidetector CT. Dynamic CT has also been shown to be an effective and non-invasive imaging technique for the diagnosis of TBM.^{8–11}

A direct view of the lesion can be obtained using both flexible and rigid bronchoscope images, for the evaluation of the degree of lumen narrowing, the state of the mucosa and the length, shape and distance of the stenosis from the vocal cords and the main carina. Specimens can also be obtained for microbiological culture, cytology and pathological evaluation.^{6,12}

In many cases, a pH-meter must be used to rule out gastroesophageal reflux disease (GERD), since the association between this and laryngotracheal stenosis has been established. GERD plays an important role in the clinical course of stenosis and in persistent treatment failure, and is also associated with the idiopathic forms of tracheal stenosis.^{13,14}

Post-Intubation and Post-Tracheotomy Stenosis

The incidence of post-intubation and post-tracheotomy tracheal stenosis (PITS and PTTS, respectively) ranges from 10% to 22%,^{15,16} but only 1%–2% require treatment.¹⁷ At present, PITS and PTTS are recognized entities, with an incidence of 4.9 cases per million inhabitants.¹⁸

PITS occurs at the endotracheal tube cuff site in one third of cases¹⁶ (Fig. 1, image 1). The main cause appears to be the loss of local blood flow due to pressure from the cuff. This ischemia starts in the first hours after intubation and resolves with the formation of web-like fibrosis in about 3–6 weeks.^{19,20} Fortunately, the introduction of both low-pressure cuffs and routine monitoring has reduced the incidence of this entity.²¹ Web-like stenosis is the most common form of PITS.²²

In contrast, PTTS occurs as a result of an abnormal tissue repair process with the formation of excessive granulation tissue around the stoma (Fig. 1, image 2) and even above or across the cartilage that was damaged during the intervention in the anterior tracheal wall.¹⁶ Many different forms of stenosis are found, including A-shaped, circumferential and granulation tissue stenoses, among

others.²² They are also frequently associated with focal tracheomalacia (Fig. 1, image 3).

Other factors that have been associated with the development of PITS and PTTS are the level of the tracheotomy stoma, prolonged intubation, traumatic intubation, history of intubation or previous tracheotomy, high dose corticosteroids, advanced age, female sex, severe respiratory failure, severe GERD, concomitant autoimmune diseases, sleep apnea-hypopnea syndrome and local radiation therapy.²³ There is still no consensus regarding the moment when a mechanically-ventilated patient with orotracheal intubation should undergo tracheotomy. Thus, Stauffer et al. indicate that intubation for less than 20 days is not associated with laryngotracheal complications or sequelae, and any possible complications may be due to poor technique.²⁴ In contrast, Whited recommends that intubation should not continue for more than 5 days, reporting a high rate of laryngotracheal lesions after that time.²⁵ In the opinion of the authors of this review, patients who require prolonged mechanical ventilation should be tracheotomized between day 7 and 14 to minimize complications secondary to intubation.

If the length of these lesions is compared, it can be seen that post-intubation stenoses have a mean length of 2.6 cm, while mean lesion length post-tracheotomy is 1.2 cm.²⁶

The typical PITS or PTTS patient profile is one of an obese female smoker with diabetes mellitus, hypertension and cardiovascular disease. Obesity is associated with a larger neck circumference, increasing the risk of cartilage trauma and fracture during tracheotomy. Patients with diabetes mellitus and cardiovascular disease will have microvascular occlusion that would contribute to ischemia caused by cuff pressure during intubation.^{27,28}

Stenosis treatment in these patients varies depending on the clinical presentation, lesion site, severity and type of stenosis, the mechanism by which it occurred and the presence of comorbidities. All these variables, together with the experience of the surgeon and endoscopist, will guide the most appropriate therapeutic approach.

The most common therapeutic endoscopic interventions at present are mechanical dilation with a pneumatic balloon, CO₂ or NdYAG laser ablation and endoluminal stent placement.²⁹

Since the pathogenic mechanism of PITS and PTTS are different, different treatments for each entity have been proposed. Zias et al. suggest that the best treatment for post-intubation stenosis consists in radial laser incisions with the aid of balloon dilation. On the other hand, they defend the use of laser ablation of the excessive granulation tissue observed in post-tracheotomy stenosis.²²

Open surgery has an important role in the treatment of complex and recurrent stenoses, in which the stenosed segment is resected surgically with subsequent end-to-end anastomosis. There is no consensus, but personalized treatment in highly experienced reference centers is advocated. Grillo and Mathisen³⁰ report a surgical mortality rate of 1.8%, but others have found rates of around 5%. Complications occur in up to 14% of cases and are related with restenosis, granulomas around the suture site, infections, bleeding and subcutaneous emphysema.^{31,32}

In patients with complex stenosis who are not candidates for surgery, or in whom this option has failed, the use of silicone stents, specifically the Dumon type, is recommended.^{33,34}

In patients with severe co-morbid conditions or those with simple stenosis, endoscopic procedures can serve as a bridge to surgery, but more importantly, they can be curative,³⁵ and are currently becoming the initial treatment of choice. Galluccio et al. were able to definitively treat 96% of simple stenoses and 69% of complex stenoses with the use of bronchoscopic technique alone.³⁶

In endoscopic balloon dilation, the entire force is delivered radially in order to minimize any mechanical damage to the mucosa while allowing better visual control of the procedure. It is indicated




Figure 3. Flowchart for the management of symptomatic stenosis. (*) Radial incisions, balloon dilation and topical application of mitomycin.

as an aid for other endoscopic techniques at various levels of the airway or as the sole technique in the case of simple, short stenoses that do not completely obstruct the airway lumen; this technique is well supported in the scientific literature.³⁷

Laser is only useful in small, narrow lesions with a reduced vertical length and stable cartilaginous skeleton, although it is widely and generally used with equally good results and low risk in the case of larger lesions. The decannulation rate is high, surgical time is reduced, and hospital stay is short-term.³⁸ For web-like stenosis, there is a variation of the technique that involves making radial incisions with the laser or with the electrocautery knife at 3, 9 and 12 o'clock before dilation.^{38–40}

The microdebrider has been shown to be effective in lesions with excessive granulation tissue.^{41–43}

Stenting is indicated in patients who do not respond to endoscopic dilation and are not candidates for surgical resection. It is important to remember that the stents indicated for this type of lesion must be easy to remove; at present, silicone stents are the most commonly used. Another alternative are fully polyurethane-coated AERO hybrid nitinol stents. These are self-expanding and can be removed, and do not require rigid bronchoscopy for implantation.^{44,45} Loss of cartilaginous support in the absence of extrinsic compression leads to migration of stents located in the subglottic region or proximal trachea. In these cases, external percutaneous fixation may be considered. Potential complications include skin infections around the external button.^{46,47} Re-stenosis as a result of the repair process itself and stent obstruction are the main reasons for re-intervention.^{23,39}

The use of topical mitomycin is controversial, but together with radial laser incisions and balloon dilation it has some beneficial effect compared to placebo at 2–3 years^{48–50} (Fig. 3).

Subglottic stenosis, mainly caused by intubation, deserves a special mention. The subglottic space refers to the section of the airway between the vocal cords and the lower fraction of the cricoid cartilage, which is the narrowest section of the larynx and the only one surrounded by a complete ring of cartilage. Its narrow diameter, inextensibility of the surrounding tissue, fragility of the coating tissue and poor vascularization make it more susceptible to trauma from intubation, re-stenosis and failure to decannulate.⁵¹ An incidence of subglottic stenosis secondary to prolonged intubation in children and adults ranging from 0.9% to 8.3% has been reported.⁵² Management is a challenge involving various strategies that must be tailored to suit each patient. For non-concentric soft, membranous stenoses with sufficient cartilaginous support and a length of

around one centimeter corresponding to Cotton-Meyer grades I and II, endoscopic techniques described above are used, with emphasis on the use of laser. The success rate is variable according to the literature, ranging between 40% and 94%.⁵³ Longer, hard, grade III and IV complex stenoses can be treated initially with endoscopic techniques, but in most cases, open reconstructive surgery will be required (surgical resection of the stenosed section, including several tracheal rings and the anterior cricoid ring, in addition to the lower half of the mucosa of the cricoid cartilage, followed by end-to-end anastomosis).^{53,54}

Dynamic Airway Obstruction: Tracheobronchomalacia and Excessive Pars Membranosa Collapse

TBM and excessive pars membranosa collapse occur in around 12% of patients with respiratory diseases.⁵⁵ In TBM, the proportion between cartilage and soft tissues is reduced from a normal ratio of 5:1 to 2:1, while in excessive pars membranosa collapse, there is atrophy and a loss of myoelastic fibers.⁵⁶ TBM, in both its local and diffuse forms, may be caused by various factors^{57,58} (Table 2). There are different ways of classifying the disease, but the functional classification (FEMOS) is the most comprehensive.⁵⁹ TBM may be asymptomatic, although it often produces cough, wheezing, stridor, dyspnea, recurrent infections, and on occasions, respiratory failure,⁶⁰ and therefore differential diagnosis is needed to rule out disease entities such as chronic obstructive pulmonary disease, asthma and bronchiectasis.⁶¹ Respiratory function tests can help in the diagnosis of concomitant obstructive pulmonary disease, but they have limited application in the diagnosis of TBM, since results are normal in up to 21% of cases.⁶² Accordingly, dynamic chest tomography and dynamic flexible bronchoscopy are often required for diagnosis^{62,63} (Fig. 1, image 3). This disease can be easily diagnosed by the performance of dynamic inhalation and exhalation maneuvers. In patients with diffuse TBM, a diagnostic test must be performed with silicone stent placement,^{61,64} along with management of comorbidities. Patients who show improvement in their symptoms will have the stent removed in preparation for surgical reconstruction by tracheobronchoplasty.⁶⁵ Patients who cannot undergo surgery due to their comorbidities will be managed with a combination of symptomatic treatment and possible definitive stenting (Fig. 4).

Although non-invasive ventilation has been proposed as a possible treatment for TBM, its role appears to be restricted to the

Table 2
Classification of Most Common Causes of Tracheobronchomalacia in Adults.

Primary
Genetic
Idiopathic
Tracheobronchomegalias (Mounier-Kuhn syndrome)
Secondary
Post-traumatic
Post-intubation
Post-tracheotomy
Chest trauma
Post-lung transplantation
Emphysema (COPD)
Chronic bronchitic infections
Chronic inflammation
Relapsing polychondritis
Extrinsic tracheal compression
Benign tumors
Malignant tumors
Cysts
Abscesses
Aortic aneurysm
Vascular rings or abnormalities

management of acute respiratory failure in TBM post-intubation, since it keeps the airway open and allows drainage of secretions. In this respect, Murgu and Colt have recently proposed diagnostic bronchoscopy via the continuous positive airway pressure (CPAP) interface, provided the patient is not in a critical situation, with the aim of determining if the patient would indeed respond to and benefit from positive airway pressure.⁶⁶ If the patient is stable, intermittent nasal pressure during the day and continuous pressure at night is recommended. This stabilizes the patient's airway and acts as a bridge to more specific and definitive treatments, such as stent implantation or surgery (tracheobronchoplasty).⁶⁷ CPAP appears to circumvent the need for tracheotomy or prolonged intubation in cases of mild to moderate TBM.⁶⁸

The human trachea is a unique and complex organ that requires rigid support to withstand the respiratory cycle, adequate vascular support for maintenance, and an epithelium that makes it resistant to aggressions from the external environment. In this respect, the flowchart for the management of persistent TBM after tracheobronchoplasty includes the possibility of performing tracheal transplantation. This is a novel treatment modality that is still under evaluation; results are uncertain, and few cases have been studied. It is reserved for very specific situations that require the resolution of post-surgical problems (as would be the case here) or a possible alternative to tracheobronchoplasty itself. Delaere, albeit outside the scope of TBM, proposed tracheal allotransplantation with temporary immunosuppression. The procedure consists in implantation of a trachea from a cadaver donor after heterotopic revascularization for 3 months on the forearm of the recipient, in which the tracheal epithelium was finally replaced by buccal mucosa in order to prevent rejection and facilitate definitive cessation of immunosuppressive treatment.⁶⁹

Tracheobronchial Stenosis in Granulomatosis With Polyangitis (Wegener's Granulomatosis)

The airway is involved in 15%–55% of cases.^{70–72} This is the only manifestation in up to 25% of patients,⁷³ and can even be irreversible. Respiratory manifestations include obstruction and/or necrosis of the nasal cartilage, subglottic stenosis, tracheal and bronchial stenoses, malacia, membrane formation, nodules and masses, alveolar infiltrates and cavitations^{74,75} (Fig. 1, image 4). Patients are usually young, under the age of 30, and mainly female.^{76,77} The main symptoms are cough, wheezing, dyspnea, stridor and hemoptysis.^{72,78} Involvement of the posterior tracheal wall is common, unlike in other disorders such as relapsing polychondritis or tracheobronchopathia osteochondroplastica.⁷⁹ Subglottic stenosis is the most common endobronchial manifestation in Wegener's granulomatosis^{80,81} and there is usually no correlation between inflammatory activity in the airway (seen on biopsy) and positive c-ANCA.^{82–86}




Figure 4. Flowchart for the management of tracheobronchomalacia. TBM: tracheobronchomalacia; TBP: tracheobronchoplasty; TM: tracheomalacia. Annual follow-up: dynamic computed tomography, dynamic bronchoscopy, pulmonary function tests. Alternative diagnosis: asthma, gastroesophageal reflux disease, vocal cord dysfunction, immunodeficiencies.

Endoscopic treatment includes injection of corticosteroids into the lesion, pneumatic balloon dilation and thermoablation. The use of stents and tracheotomy must be avoided, since these procedures have their own complications. Generally surgical resection with re-anastomosis is used in highly selected cases.^{78,79,87–92}

Intralesional application of long-acting corticosteroids (60–80 mg methylprednisolone acetate) together with endoscopic dilation appears to be an effective treatment.^{93–95}

Tracheobronchial Stenosis in Amyloidosis

Subglottic obstruction is the most common form (0.5% of all symptomatic lesions in the tracheobronchial tree and 23% of all benign symptomatic lesions). Simultaneous involvement of the parenchyma and the tracheobronchial tree is uncommon.⁹⁶

Amyloidosis in the tracheal mucosa can cause disease ranging from diffuse lesions to masses simulating tumors.⁹⁷ Diagnosis is determined when a biopsy of the lesion shows red Congo staining with apple-green birefringence under polarized light. Irregular narrowing of the lumen, wall thickening and irregular calcifications can be observed on endoscopy.⁹⁶ Some patients can have airway obstruction or hemoptysis: in these cases, laser is the treatment of choice.^{98–100} In patients with diffuse disease, Kurrus et al. documented the regression of endobronchial amyloid deposits after 10 radiotherapy sessions of 20 Gy each.¹⁰¹

Tracheobronchial Stenosis Due to Tuberculosis

An endobronchial component is present in 10%–40% of active pulmonary tuberculosis,^{102,103} with involvement of the primary bronchi in 60%–95% of cases.¹⁰⁴ This is most frequently seen when diagnosis and treatment are delayed.^{105,106} The most likely cause is lymph node involvement with subsequent fistulization toward the adjacent bronchi.¹⁰⁷ Endobronchial tuberculosis can present as a caseous/edematous, hyperemic, fibrostenotic, granular, tumor or ulcerative lesion.^{105,108} It often presents as a white, gelatinous, polypoid lesion (Fig. 1, image 5).

Endoscopic treatment includes thermoablation and serial balloon dilations. Stent implantation can be considered for symptomatic irreversible scar lesions or extrinsic compression of the airway.¹⁰⁹

Tracheobronchial Stenosis in Tracheobronchopathia Osteochondroplastica

Tracheobronchopathia osteochondroplastica is a rare, non-tumorous disease that affects the trachea and to a lesser extent the primary bronchi, presenting as submucous nodules of cartilaginous or bony origin projecting into the airway lumen.^{110–113} These nodules can be of different sizes but generally measure between 1 mm and 3 mm and are located in the anterolateral tracheal wall with no posterior wall involvement.¹¹⁴ They can cause deformity and narrowing of the trachea, although in only 10% of cases do they occupy more than 50% of the lumen.¹¹⁰

Higher than normal concentrations of certain cytokines (BMP-2, TGF-B1) have led to the suggestion that this disorder may be the result of metaplasia of the mesenchymal connective tissue adjacent to the submucosa.¹¹⁵

This disease is not associated with smoking, and prevalence does not differ between men and women. The majority of cases are diagnosed in middle-aged subjects.^{116,117}

CT reveals densely calcified nodules in the submucosa protruding into the anterolateral wall of the airway lumen.^{110,112,114} These same findings are confirmed on bronchoscopic visualization (Fig. 1, image 6). If the appearance is typical, no biopsy is necessary.

If biopsy is performed, bronchial submucosa is found to be bony or calcified.¹¹⁰ Tracheobronchopathia osteochondroplastica is a slow, benign disease that rarely causes complications such as post-obstructive pneumonias or respiratory failure.¹¹⁶ If obstructive symptoms are present, most patients are treated with endoscopic laser ablation and stents.^{110,113,116} Surgical resection is rarely required.

Idiopathic Tracheal Stenosis

In most cases, this type of stenosis is located in the subglottic region or in the upper third of the trachea.^{118–120} It occurs mainly in women, suggesting that estrogens have an important role in this entity.^{118–121} Other authors suggest that it may be associated with GERD.^{122,123}

Although evaluation of the flow-volume loop may suggest the diagnosis, multi-slice CT and bronchoscopy (Fig. 1, image 7) are essential for confirmation.^{124–126}

Histological specimens retrieved during bronchoscopy reveal dense fibrosis and moderate inflammatory infiltration with a significant amount of fibroblast formation.¹²⁷

While surgery remains the definitive treatment,^{48,128,129} lesions smaller than 1 cm can be successfully treated with endoscopy techniques, performing radial incisions followed by balloon dilation and the topical application of mitomycin C. The use of removable stents can be considered in patients with recurrent lesions who are not candidates for surgery or as a bridge to surgical intervention. For simple stenoses, at least three bronchoscopic sessions are recommended before surgery is considered. Injection of steroids into the lesion or the application of mitomycin C has been used to prevent re-stenosis after endoscopic treatment.^{120,48,130} Surgical resection is the treatment of choice for complex stenotic lesions.

Tracheobronchial Stenosis in Relapsing Polychondritis

Relapsing polychondritis is a multi-system autoimmune disease with recurrent inflammatory episodes affecting cartilaginous structures, such as the ears, nose, peripheral joints, larynx and tracheobronchial tree.^{131,132} It is more common between the fourth and fifth decades of life, and is not gender-predominant.¹³¹

During the course of this disease, approximately half of patients will have pulmonary and airway involvement, including for example, subglottic stenosis, focal or diffuse malacia and tracheobronchial stenosis. Dynamic chest CT with slices obtained in inspiration and forced expiration is the imaging test of choice. Focal stenosis, thickening of the tracheal wall with or without calcifications and expiratory collapse associated with concentric malacia may be observed.¹³³ PET imaging may be useful for diagnosis and for evaluating response to treatment.^{134,135}

Some patients require interventions such as balloon dilation, stents or tracheotomy. In those in whom TBM is an added factor, intermittent CPAP, expectorants and flutter valves may be used to avoid mucostasis and superinfection. Medical treatment generally consists of anti-inflammatory treatment with corticosteroids combined with methotrexate, azathioprine or cyclophosphamide.¹³¹ Some studies support the use of new immunomodulatory therapies, such as etanercept, infliximab and rituximab.^{136–140}

Tracheobronchial Stenosis in Sarcoidosis

The airway may be compromised even in the absence of parenchymal involvement.^{141–143}

The formation of granulomas gives the mucosa a cobblestone appearance.¹⁴¹ Other forms of involvement are erythema, edema and plaque formation. Narrowing of the airway secondary to

scar stenosis or extrinsic compression due to mediastinal lymphadenopathies is rare.¹⁴⁴

Cough is the most common clinical manifestation of this disease when it presents in the main airway.^{141,145–149} Endoscopic findings range from single or multiple stenoses to diffuse airway narrowing.^{141,150,151}

In patients with mild symptoms, inhaled corticosteroids should be sufficient treatment, but systemic corticosteroids may be added.¹⁴¹ Bronchoscopic procedures, for example, pneumatic dilation and thermoablation, are required in some cases, in addition to attempts with intralesional corticosteroids.

Post-lung Transplantation Bronchial Stenosis

Post-transplantation bronchial stenoses are a significant source of morbidity and mortality, and are the result of the anastomosis repair process. It occurs at a rate of between 16% and 33%¹⁵² and mortality ranges between 2% and 4%.^{153–159}

These stenoses are vulnerable to ischemia, since the circulation of the bronchial arteries is not generally immediately re-established and perfusion depends on retrograde flow from the pulmonary artery until a collateral flow is established after a period of 2–4 weeks.¹⁶⁰ Other factors such as rejection, immunosuppressive treatment, infections or inadequate organ preservation have been involved in changing the course of the repair process.^{161,162} Since two thirds of these patients have concomitant bronchomalacia, pneumatic balloon dilation is usually a temporary solution, and stents are required in most cases.^{163–166} De Gracia et al. have reported that stents are required in only half of cases.¹⁶⁷ Silicone or hybrid stents¹⁶⁶ must be used only for recurrent stenoses that have not responded to 3–4 balloon dilations or in cases of severe symptomatic focal malacia.¹⁶⁵

Recently Dutau et al., in a series of 17 cases, proposed the use of silicone stents, pointing out the resolution of stenosis and healing of the anastomosis in most patients (with fewer side effects than the self-expanding metallic stents generally used), after which the stent can be removed.¹⁶⁸ One of the major problems encountered is the location of the anastomosis sutures that generally make it difficult to adapt the stent to the anatomy of the patient, resulting in migration and/or obstruction of the entrances to the upper lobes. These complications, particularly in the case of stenosis of the intermediate bronchus, appear to be resolved by placing the tracheotomy arm of a modified Montgomery T-tube at the entrance to the right upper lobe, thus maintaining patency.¹⁶⁹

Conclusion

Benign central airway lesions frequently call for therapeutic bronchoscopy procedures. Treatment of these disorders requires immediate stabilization, detailed evaluation, meticulous planning and tailored treatment. An evaluation of each lesion that encompasses physiopathology and the natural history of the disease is required. Treatment must be planned by a multidisciplinary team that includes interventional pulmonologists, chest surgeons, anesthetists, ear, nose and throat specialists and radiologists. In practice, therapeutic bronchoscopy and tracheal surgery are interrelated, complementary procedures.

Conflict of Interests

None.

Funding

None.

Acknowledgements

None.

References

- Ernst A, Feller-kopman D, Becker HD, Metha AC. Central airway obstruction. *Am J Respir Crit Care Med.* 2004;169:1278–97.
- Ashiku SK, Kuzucu A, Grillo HC, Wright CD, Wain JC, Lo B, et al. Idiopathic laryngotracheal stenosis: effective definitive treatment with laryngotracheal resection. *J Thorac Cardiovasc Surg.* 2004;127:99–107.
- Mark Ej, Meng F, Kradin RL, Mathisen DJ, Matsubara O. Idiopathic tracheal stenosis: a clinicopathological study of 63 cases and comparison of the pathology with condromalacia. *Am J Surg Pathol.* 2008;32:1138–43.
- Freitag L, Ernst A, Unger M, Kovitz K, Marquette CH. A proposed classification system of central airway stenosis. *Eur Respir J.* 2007;30:7–12.
- Noppen M, Meysman M, D'Haese J, Schlessier M, Vincken W. Interventional bronchoscopy: 5-year experience at the Academic Hospital of the Vrije Universiteit Brussel (AZ-VUB). *Acta Clin Belg.* 1997;52:371–80.
- Carretta A, Melloni G, Ciriaco P, Libretti L, Casiraghi M, Bandiera A, et al. Pre-operative assessment in patients with postintubation tracheal stenosis: rigid and flexible bronchoscopy versus spiral CT scan multiplanar reconstructions. *Surg Endosc.* 2006;20:905–8.
- Acres JC, Kryger MH. Clinical significance of pulmonary function tests: upper airway obstruction. *Chest.* 1981;80:207–11.
- Taha MS, Mostafa BE, Fahmy M, Ghaffar MK, Ghany EA. Spiral CT virtual bronchoscopy with multiplanar reformating in the evaluation of post-intubation tracheal stenosis: comparison between endoscopic, radiological and surgical findings. *Eur Arch Otorhinolaryngol.* 2009;266:863–6.
- Müller A. Modern diagnostics of tracheal stenosis. *Laryngorhinootologie.* 2004;83:381–6.
- Callanan V, Gillmore K, Field S, Beaumont A. The use of magnetic resonance imaging to assess tracheal stenosis following percutaneous dilatational tracheostomy. *J Laryngol Otol.* 1997;111:953–7.
- Boiselle PM, O'Donnell CR, Bankier AA, Ernst A, Millet ME, Potemkin A, et al. Tracheal collapsibility in healthy volunteers during forced expiration: assessment with multidetector CT. *Radiology.* 2009;252:255–62.
- Mostafa BE. Endoluminal stenting for tracheal stenosis. *Eur Arch Otorhinolaryngol.* 2003;260:465–8.
- Cotton RT, O'Connor DM. Paediatric laryngotracheal reconstruction: 20 years' experience. *Acta Otorhinolaryngol Belg.* 1995;49:367–72.
- Toohill RJ, Ulualp SO, Shaker R. Evaluation of gastroesophageal reflux with laryngotracheal stenosis. *Ann Otol Rhinol Laryngol.* 1998;107:1010–4.
- McEwen W. Clinical observations on the introduction of the tracheal tubes by the mouth instead of performing tracheostomy or laryngotomy. *Br Med J.* 1880;2:122–4.
- Grillo HC, Donahue DM, Mathisen DJ, Wain JC, Wright CD. Postintubation tracheal stenosis. Treatment and results. *J Thorac Cardiovasc Surg.* 1995;109:486–92.
- Dutau H. Tracheal stenosis endoscopic treatment. In: Proceedings of the 12th world congress for bronchology, 2002, Boston. Bologna: Monduzzi Editore; 2002. p. 82–8.
- Nouraei SA, Ma E, Patel A, Howard DJ, Sandhu GS. Estimating the population incidence of adult post-intubation laryngotracheal stenosis. *Clin Otolaryngol.* 2007;32:411–2.
- Weymuller EA. Laryngeal injury from prolonged endotracheal intubation. *Laryngoscope.* 1988;98:1–15.
- Wain JC. Postintubation tracheal stenosis. *Chest Surg Clin N Am.* 2003;13:231–46.
- Nordi U. The trachea and cuff-induced tracheal injury. An experimental study on causative factors and prevention. *Acta Otolaryngol Suppl.* 1977;345:1–71.
- Zias N, Chroneou A, Tabba MK, González AV, Gray AW, Lamb CR, et al. Post tracheostomy and post intubation tracheal stenosis: report of 31 cases and review of the literature. *BMC Pulm Med.* 2008;8:18–24.
- Koshkareva Y, Gaughan JP, Soliman AM. Risk factors for adult laryngotracheal stenosis: a review of 74 cases. *Ann Otol Rhinol Laryngol.* 2007;116:206–10.
- Stauffer JL, Olson DE, Petty TL. Complications and consequences of endotracheal intubation and tracheotomy. A prospective study of 150 critically ill adult patients. *Am J Med.* 1981;70:65–76.
- Whited RE. A prospective study of laryngotracheal sequelae in long-term intubation. *Laryngoscope.* 1984;94:367–77.
- McCaffrey TV. Classification of laryngotracheal stenosis. *Laryngoscope.* 1992;102:1335–40.
- Cavaliere S, Bezzoli M, Toninelli C, Foccoli P. Management of post-intubation tracheal stenosis using the endoscopic approach. *Monaldi Arch Chest Dis.* 2007;67:73–80.
- Sarper A, Ayten A, Eser I, Ozbudak O, Demircan A. Tracheal stenosis after tracheostomy or intubation: review with special regard to cause and management. *Tex Heart Inst J.* 2005;32:154–8.
- Bagheri R, Majidi M, Khadivi E, Sharifian A, Tabari A. Outcome of surgical treatment for proximal long segmental post intubation tracheal stenosis. *J Cardiothorac Surg.* 2013;8:35.

30. Grillo HC, Mathisen DJ. In: Farrel EM, Keon WJ, editors. *Surgical management of tracheal strictures*, vol. 68. Philadelphia: WB Saunders; 1988. p. 511–24.
31. Wright CD, Grillo HC, Wain JC, Wong DR, Donahue DR, Gassert HA, et al. Anastomotic complications after tracheal resection: prognostic factors and management. *J Thorac Cardiovasc Surg*. 2004;128:731–9.
32. Fernández RB, Moran AM, Vidal MJ, Barro JVC, García AS. Resection with end to end anastomotic postintubation tracheal stenosis. *Acta Otorrinolaringol Esp*. 2007;58:16–9.
33. Tsakridis K, Darwiche K, Visouli AN, Zaragoulidis P, Machairiotis N, Christofis C, et al. Management of complex benign post tracheostomy tracheal stenosis with bronchoscopic insertion of silicon tracheal stents in patients with failed or contraindicated surgical reconstruction of trachea. *J Thorac Dis*. 2012;4: 32–40.
34. Dutau H. Airway stenting for benign tracheal stenosis: what is really behind the choice of the stent? *Eur J Cardiothorac Surg*. 2011;40:924–5.
35. Brichet A, Verkindre C, Dupont J, Carlier ML, Darras J, Wurtz A, et al. Multidisciplinary approach to management of postintubation tracheal stenosis. *Eur Respir J*. 1999;13:888–93.
36. Galluccio G, Lucantoni G, Battistoni P, Paone G, Batzella S, Lucifora V, et al. Interventional endoscopy in the management of benign tracheal stenosis: definitive treatment at long-term follow-up. *Eur J Cardiothorac Surg*. 2009;35: 429–34.
37. McArdle J, Gildea T, Mehta A. Balloon bronchoplasty: its indications, benefits and complications. *J Bronchol*. 2005;4:123–7.
38. Metha AC, Lee FY, Cordasco EM, Kirby T, Eliachar I, De Boer G. Concentric tracheal and subglottic stenosis. Management using the Nd-YAG laser for mucosal sparing followed by gentle dilatation. *Chest*. 1993;104:673–7.
39. Tremblay A, Coulter T, Metha AC. Modification of a mucosal-sparing technique using electrocautery and balloon dilation in the endoscopic management of web-like airway stenosis. *J Bronchol*. 2003;10:268–71.
40. Noppen M, Schlessier M, Meysman M, Haese JD, Peche R, Vincken W. Bronchoscopic balloon dilatation in the combined management of postintubation stenosis of the trachea in adults. *Chest*. 1997;112:1136–40.
41. Flint PW. Powered surgical instruments for laryngeal surgery. *Otolaryngol Head Neck*. 2000;122:263–6.
42. Simoni P, Peters GE, Magnuson JS, Carroll WR. Use of the endoscopic microdebrider in the management of airway obstruction from laryngotracheal carcinoma. *Ann Otol Rhinol Laryngol*. 2003;112:11–3.
43. Lunn W, Garland R, Ashiku S, Thurer RL, Feller-Kopman D, Ernst A. Microdebrider bronchoscopy: a new tool for the interventional bronchoscopist. *Ann Thorac Surg*. 2005;80:1485–8.
44. Dumon JF. A dedicated tracheobronchial stent. *Chest*. 1990;97:328–32.
45. Freitag L, Tekolf E, Stamatis G. Clinical evaluation of a new bifurcated dynamic airway stent: a 5 year experience with 135 patients. *Thorac Cardiovasc Surg*. 1997;45:6–12.
46. Colt HG, Harrell J, Neuman TR, Robbins T. External fixation of subglottic tracheal stents. *Chest*. 1994;105:1653–7.
47. Majid A, Fernández-Bussy S, Kent M, Folch E, Fernández L, Cheng G, et al. External fixation of proximal tracheal airway stents: a modified technique. *Ann Thorac Surg*. 2012;93:167–9.
48. Smith ME, Elstad M. Mytomycin C and the endoscopic treatment of laryngotracheal stenosis: are two applications better than one? *Laryngoscope*. 2009;119:272–83.
49. Cortés de Miguel S, Cabeza Barrera J, Gallardo Medina M, Cassini Gómez de Cádiz LF, Salmerón García A, Rodríguez Lucas F. Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis. *Farm Hosp*. 2011;35:32–5.
50. Veen Ej, Dikkers FG. Topical use of MMC in the upper aerodigestive tract: a review on the side effects. *Eur Arch Otorhinolaringol*. 2010;267: 327–34.
51. Duynstee MLG, Monnier P. Subglottic stenosis after endolaryngeal intubation in infants and children: results of wound healing process. *Int J Pediatr Otorhinolaringol*. 2002;62:181–6.
52. Figueroa JN, Delgado TL, Osorio MC. Realización de traqueostomía temprana ante la posibilidad de desarrollarse una estenosis subglótica. *Acta Colomb Otorrinolaringol Cirugía Cabeza Cuello*. 2001;29:50–4.
53. Bathavachalam S, McClay JE. Endoscopic management of subglottic stenosis. *Otolaryngol Head Neck Surg*. 2008;139:551–9.
54. Wright C. Surgical management of subglottic stenosis. *Operative Techniques in cardiac and Thoracic Surg*. 2008;13:53–65.
55. Ikeda S, Hanawa T, Konishi T, Adachi M, Sawi S, Chiba W. Diagnosis, incidence, clinicopathology and surgical treatment of acquired tracheobronchomalacia. *Nihon Kyobu Shikkai Gakkai Zasshi*. 1992;30:1028–35.
56. Jokinen K, Palva T, Sutinen S, Nuutilainen J. Acquired tracheobronchomalacia. *Ann Clin Res*. 1997;9:52–7.
57. Feist JH, Johnson TH, Wilson RJ. Acquired tracheobronchomalacia: etiology and differential diagnosis. *Chest*. 1975;68:340–5.
58. Ernst A, Majid A, Feller-Kopman D, Guerrero J, Boiselle P, Loring S. Airway stabilization with silicon stents for treating adult tracheobronchomalacia: a prospective observational study. *Chest*. 2007;132:609–16.
59. Murgu SD, Colt HG. Tracheobronchomalacia and excessive dynamic airway collapse. *Respirology*. 2006;11:388–406.
60. Nuutilainen J. Acquired tracheobronchomalacia. *Eur J Respir Dis*. 1982;63:380–7.
61. Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review. *Chest*. 2005;127:984–1005.
62. Majid A, Sosa A, Ernst A, Feller-Kopman D, Folch E, Singh A, et al. Pulmonary function and flow volume loop patterns in patients with tracheobronchomalacia. *Respir Care*. 2013;58:1521–6.
63. Zhang J, Hasegawa I, Feller-Kopman D, Boiselle PM. 2003 AUR Memorial Award Dynamic expiratory volumetric CT imaging of the central airways: comparison of standard-dose and low-dose techniques. *Acad Radiol*. 2003;10: 719–24.
64. Wright CD. Tracheomalacia. *Chest Surg Clin N Am*. 2003;13:349–57.
65. Majid A, Guerrero J, Gangadharn S, Feller-Kopman D, Boiselle P, DeCamp M. Tracheobronchoplasty for severe tracheobronchomalacia: a prospective outcome analysis. *Chest*. 2008;134:801–7.
66. Murgu S, Colt H. Tracheobronchomalacia and excessive dynamic airway collapse. *Clin Med Chest*. 2013;43:527–55.
67. Ferguson GT, Benoit J. Nasal continuous positive airway pressure in the treatment of tracheobronchomalacia. *Am Rev Respir Dis*. 1993;147:457–61.
68. Hegde HV, Bhat RL, Shanbag MD, Bharat MP, Rao PR. Unmasking of tracheobronchomalacia following short-term mechanical ventilation in a patient of adult respiratory distress syndrome. *Indian J Anaesth*. 2012;56:171–4.
69. Delaere PR. Tracheal transplantation. *Curr Opin Pulm Med*. 2012;18: 313–20.
70. Daum TE, Specks U, Colby TV, Edell ES, Brutinel MW, Prakash UB. Tracheobronchial involvement in Wegener's granulomatosis. *Am J Respir Crit Care Med*. 1995;151:522–6.
71. Gluth MB, Shinners PA, Kasperbauer JL. Subglottic stenosis associated with Wegener's granulomatosis. *Laryngoscope*. 2003;113:1304–7.
72. Cordier JF, Valeyre D, Guillemin L, Loire R, Brechet JM. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. *Chest*. 1990;97:906–12.
73. Lee AS, Finkelman JD, Peikert T, Hummel AM, Viss MA, Jacob GL. Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma. *Clin Exp Immunol*. 2006;146:15–20.
74. McCallister JW, Bowling M, Chin R, Conforti J, Haponik E. Bronchoscopy in the diagnosis of Wegener granulomatosis. *Clin Pulm Med*. 2007;14:179–82.
75. Summers RM, Aggarwal NR, Sneller MC, Cowan MJ, Wood BJ, Langford CA. CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis. *Chest*. 2002;121:242–50.
76. Lebowitz RS, Hoffman GS, Leavitt RY, Kerr GS, Travis WD, Kammerer W. The management of subglottic stenosis in patients with Wegener's granulomatosis. *Laryngoscope*. 1992;102:1341–5.
77. Alaani A, Hogg RP, Drake Lee AB. Wegener's granulomatosis and subglottic stenosis: management of the airway. *J Laryngol Otol*. 2004;118: 786–90.
78. McDonald TJ, Neel HB, DeRemee RA. Wegener's granulomatosis of the subglottic and upper portion of the trachea. *Ann Otol Rhino Laryngol*. 1982;91: 588–92.
79. Langford CA, Sneller MC, Hallahan CW, Hoffman GS, Kammerer WA, Talar-Williams C, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. *Arthritis Rheum*. 1996;39:1754–60.
80. Polychronopoulos VS, Prakash UB, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener's granulomatosis. *Rheum Dis Clin North Am*. 2007;33:755–75.
81. Sreaton NJ, Sivasothy P, Flower CD, Lockwood CM. Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT. *Clin Radiol*. 1998;53:809–15.
82. Devaney KO, Travis WD, Hoffman G, Leavitt R, Lebowitz RS, Fauci AS. Interpretation of head and neck biopsies in Wegener's granulomatosis. *Am J Surg Pathol*. 2003;22:107–10.
83. Ackerman Z, Orbach H, Burnstein M, Breuer R. Transbronchial biopsies in Wegener's granulomatosis. *Ann Intern Med*. 1986;105:801–2.
84. Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopathological study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. *Am J Surg Pathol*. 1990;14:1112–25.
85. Cohen-Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. *Arch Intern Med*. 1989;149:2461–5.
86. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. *Am J Surg Pathol*. 1991;15:315–33.
87. Shapshay SM, Valdez TA. Bronchoscopic management of benign stenosis. *Chest Surg Clin N Am*. 2001;11:749–68.
88. Herridge MS, Pearson FG, Downey GP. Subglottic stenosis complicating Wegener's granulomatosis: surgical repair as a viable treatment option. *J Thorac Cardiovasc Surg*. 1996;111:961–6.
89. Eliachar I, Chan J, Akst L. New approaches to the management of subglottic stenosis in Wegener's granulomatosis. *Cleve Clin J Med*. 2002;69: 149–51.
90. Shesky FD, Mathur PN. Long term results of fiberoptic bronchoscopic balloon dilation in the management of benign tracheobronchial stenosis. *Chest*. 1998;14:796–800.
91. Utzig MJ, Warzelhan J, Wertzel H, Berwanger I, Hasse J. Role of thoracic surgery and interventional bronchoscopy in Wegener's granulomatosis. *Ann Thorac Surg*. 2002;74:1948–52.
92. Stappaerts I, van Laer C, Deschepper K, van de Heyning P, Vermeire P. Endoscopic management of severe subglottic stenosis in Wegener's granulomatosis. *Clin Rheumatol*. 2000;19:315–7.

93. Cobb WB, Sudderth JF. Intralesional steroids in laryngeal stenosis. *Arch Otolaryngol*. 1972;96:52–6.
94. Wolter NE, Ooi EH, Witterick IJ. Intralesional corticosteroid injection and dilatation provides effective management of subglottic stenosis in Wegener's granulomatosis. *Laryngoscope*. 2010;120:2452–5.
95. Hoffman GS, Thomas-Golbanov CK, Chan J, Akst LM, Eliachar I. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. *J Rheumatol*. 2003;30:1017–21.
96. O'Reagan A, Fenlon HM, Beamis JF, Steele MP, Skinner M, Berk JL. Tracheobronchial amyloidosis. The Boston University experience from 1984 to 1999. *Medicine (Baltimore)*. 2000;79:69–79.
97. Gillmore JD, Hawkins PN. Amyloidosis and the respiratory tract. *Thorax*. 1999;54:444–51.
98. Thompson PJ, Ryan G, Laurence BH. Laser photoradiation therapy for tracheobronchial amyloid. *Aust N Z J Med*. 1986;16:229–30.
99. Madden B, Lee M, Paruchuru P. Successful treatment of endobronchial amyloidosis using Nd:YAG laser therapy as an alternative to lobectomy. *Monaldi Arch Chest Dis*. 2001;56:27–9.
100. Yap JC, Wang YT, Poh SC. A case of primary diffuse tracheobronchial amyloidosis treated by laser therapy. *Sing Med J*. 1992;33:198–200.
101. Kurrus JA, Hayes JK, Hiodal JR, Menendez NM, Elstad MR. Radiation therapy for tracheobronchial amyloidosis. *Chest*. 1998;114:1489–92.
102. Smith LS, Schillaci RF, Sarlin RF. Endobronchial tuberculosis: serial fiberoptic bronchoscopy. *Chest*. 1987;91:644–7.
103. Hudson EH. Respiratory tuberculosis: clinical diagnosis. In: Heaf ERG, editor. *Symposium on tuberculosis*. London: Cassel and Co; 1957. p. 321–464.
104. Kashyap S, Mohapatra PR, Saini V. Endobronchial tuberculosis. *Indian J Chest Dis Allied Sci*. 2003;45:247–56.
105. Park MJ, Woo IS, Son JW. Endobronchial tuberculosis with expectoration of tracheal cartilages. *Eur Respir J*. 2000;15:800–2.
106. Chung HS, Lee JH. Bronchoscopic assessment of the evolution of endobronchial tuberculosis. *Chest*. 2000;117:385–92.
107. Lee JH, Park SS, Lee DH, Yang SC, Yoo BM. Endobronchial tuberculosis: clinical and bronchoscopic features in 121 cases. *Chest*. 1992;102:990–4.
108. Steinfeld DP, Smallwood D, Antippa P, Irving LB. Endobronchial extension of granulomatous lymphadenitis in a HIV-positive man with immune reconstitution syndrome. *Respiriology*. 2009;14:1064–6.
109. Chhajed PN, Malouf MA, Glanville AR. Bronchoscopic dilatation in the management of benign tracheobronchial stenosis. *Intern Med J*. 2001;31:512–6.
110. Leske V, Lazor R, Coetmeur D. Tracheobronchopathia osteochondroplastica: a study of 41 patients. *Medicine (Baltimore)*. 2001;80:378–90.
111. Abu-Hijleh M, Lee D, Braman SS. Tracheobronchopathia osteochondroplastica: a rare large airway disorder. *Lung*. 2008;186:353–9.
112. Restrepo S, Pandit M, Villamil MA. Tracheobronchopathia osteochondroplastica: helical CT findings in 4 cases. *J Thorac Imaging*. 2004;19:112–6.
113. Nienhuis DM, Prakash UB, Edell ES. Tracheobronchopathia osteochondroplastica. *Ann Otol Rhinol Laryngol*. 1990;99:689–94.
114. Zack JR, Rozenshtain A. Tracheobronchopathia osteochondroplastica: report of 3 cases. *J Comput Assist Tomogr*. 2002;26:33–6.
115. Tajima K, Yamakawa M, Katagiri T. Immunohistochemical detection of bone morphogenetic protein-2 and transforming growth factor B1 in tracheobronchopathia osteochondroplastica. *Virchows Archiv*. 1997;431:359–63.
116. Jabbardarjani HR, Radpey B, Kharabian S. Tracheobronchopathia osteochondroplastica: presentation of ten cases and review of the literature. *Lung*. 2008;186:293–7.
117. Hayes Jr D. Tracheopathia osteoplastica misdiagnosed as asthma. *J Asthma*. 2007;44:253–5.
118. Lorenz RR. Adult laryngotracheal stenosis: etiology and surgical management. *Curr Opin Otolaryngol Head Neck Surg*. 2003;11:467–72.
119. Damrose EJ. On the development of idiopathic subglottic stenosis. *Med Hypotheses*. 2008;71:122–5.
120. Valdez TA, Shapshay SM. Idiopathic subglottic stenosis revisited. *Ann Otol Rhino Laryngol*. 2002;111:690–5.
121. Dedo HH, Catten MD. Idiopathic progressive subglottic stenosis: findings and treatment in 52 patients. *Ann Otol Rhinol Laryngol*. 2001;110:305–11.
122. Maronian NC, Azadeh H, Waugh P. Association of laryngopharyngeal reflux disease and subglottic stenosis. *Ann Otol Rhinol Laryngol*. 2001;110:606–12.
123. Terra RM, de Medeiros IL, Minamoto H. Idiopathic tracheal stenosis: successful outcome with antigastroesophageal reflux disease therapy. *Ann Thorac Surg*. 2008;85:1438–9.
124. Boiselle PM. Imaging of the large airways. *Clin Chest Med*. 2008;29:181–93.
125. Javidan-Nejad C. MDCT of trachea and main bronchi. *Radiol Clin North Am*. 2010;48:157–76.
126. Gotway MB, Golden JA, LaBerge JM. Benign tracheobronchial stenoses: changes in short-term and long-term pulmonary function testing after expandable metallic stent placement. *J Comput Assist Tomogr*. 2002;26:564–72.
127. Park SS, Streitz Jr JM, Rebeiz EE. Idiopathic subglottic stenosis. *Arch Otolaryngol Head Neck Surg*. 1995;121:894–7.
128. Liberman M, Mathisen DJ. Treatment of idiopathic laryngotracheal stenosis. *Semin Thorac Cardiovasc Surg*. 2009;21:278–83.
129. D'Andrilli A, Ciccone AM, Venuta F. Long-term results of laryngotracheal resection for benign stenosis. *Eur J Cardiothorac Surg*. 2008;33:440–3.
130. Roediger FC, Orloff LA, Courey MS. Adult subglottic stenosis: management with laser incisions and mitomycin-C. *Laryngoscope*. 2008;118:1542–6.
131. Lahmer T, Treiber M, von Werder A. Relapsing polychondritis: an autoimmune disease with many faces. *Autoimmun Rev*. 2010;9:540–6.
132. Rafeq S, Trentham D, Ernst A. Pulmonary manifestations of relapsing polychondritis. *Clin Chest Med*. 2010;31:513–8.
133. Grenier PA, Beigelman-Aubry C, Brillet PY. Nonneoplastic tracheal and bronchial stenosis. *Radiol Clin North Am*. 2009;47:243–60.
134. De Geeter F, Vandencastele SJ. Fluorodesoxyglucose PET in relapsing polychondritis. *N Engl J Med*. 2008;358:536–7.
135. Sato M, Hiyama T, Abe T, Ito Y, Yamaguchi S, Uchiumi K, et al. F-18 FDG PET/CT in relapsing polychondritis. *Ann Nucl Med*. 2010;24:687–90.
136. Scharader C, Lohmann J. Successful therapy with etanercept in relapsing polychondritis. *Z Rheumatol*. 2010;69:356–8.
137. Carter JD. Treatment of relapsing polychondritis with a TNF antagonist. *J Rheumatol*. 2005;32:1413.
138. Mpofo S, Estrach C, Curtis J, Moots RJ. Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab. *Rheumatology*. 2003;42:1117–8.
139. Abdwani R, Koletkekatt AA, al Abri R. Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): first case report. *Int J Pediatr Otorhinolaryngol*. 2012;76:1061–4.
140. Leroux G. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients. *Arthritis Rheum*. 2009;61:577–82.
141. Polychronopoulos VS, Prakash USB. Airway involvement in sarcoidosis. *Chest*. 2009;136:1371–80.
142. Baughman RP, Lower EE, Tami T. Upper airway: sarcoidosis of the upper airway respiratory tract (SURT). *Thorax*. 2010;65:181–6.
143. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. *Chest*. 2001;120:881–6.
144. Brandstetter RD, Messina MS, Sprince NL. Tracheal stenosis due to sarcoidosis. *Chest*. 1981;80:656.
145. Dempsey OJ, Patterson EW, Kerr KM. Sarcoidosis. *BMJ*. 2009;339:3206.
146. Naccache J-M, Laveole A, Nunes H. High-resolution computed tomographic imaging of airways in sarcoidosis patients with airflow obstruction. *J Comput Assit Tomogr*. 2008;32:905–12.
147. Hansell DM, Milne DG, Wilsher ML. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. *Radiology*. 1998;209:697–704.
148. Wang M, Yasufuku K, Nakayama T, Herth JF, Sekine Y, Shibuya K. Endobronchial ultrasound: new insight for the diagnosis of sarcoidosis. *Eur Respir J*. 2007;29:1182–6.
149. Fernández-Villar A, Botana MI, Leiro V, Represas C, González A, Mosteiro M, et al. Clinical utility of transbronchial needle aspiration of transbronchial lymph node in the diagnosis of sarcoidosis in stages I and II. *Arch Bronconeumol*. 2007;43:495–500.
150. Udwadia ZF, Pilling JR, Jenkins PF. Bronchoscopic and bronchographic findings in 12 patients with sarcoidosis and severe or progressive airways obstructions. *Thorax*. 1990;45:272–5.
151. Chambellan A, Turbie P, Nunes H. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function and evolution. *Chest*. 2005;127:472–81.
152. Santacruz JF, Metha AC. Airway complications and management after lung transplantation: ischemia, dehiscence and stenosis. *Proc Am Thorac Soc*. 2009;6:79–93.
153. Schmid RA, Boehler A, Speich R, Frey HR, Russi EW, Weder W. Bronchial anastomotic complications following lung transplantation: still a major cause of morbidity? *Eur Respir J*. 1997;10:2872–5.
154. Van de Wauwer C, van Raemdonck D, Verleden GM, Dupont L, de Leyn P, Coosemans W. Risk factors for airway complications within the first year after lung transplantation. *Eur J Cardiothorac Surg*. 2007;31:703–10.
155. Mulligan MS. Endoscopic management of airway complications after lung transplantation. *Chest Surg Clin N Am*. 2001;11:907–15.
156. Murthy SC, Blackstone EH, Gildea TR, Gonzalez-Stawinski GV, Feng J, Budde M, et al. Impact of anastomotic airway complications after lung transplantation. *Ann Thorac Surg*. 2007;84:401–9.
157. Date H, Trulock EP, Arcidi JM, Sundaresan S, Cooper JD, Patterson GA. Improved airway healing after lung transplantation: an analysis of 384 bronchial anastomoses. *J Thorac Cardiovasc Surg*. 1995;110:1424–32.
158. Herrera JM, McNeil KD, Higgins RS, Couliden RA, Flowe CD, Nashef SA. Airway complications after lung transplantation: treatment and long-term outcome. *Ann Thorac Surg*. 2001;71:989–93.
159. Ruttman E, Ulnar H, Marchese M, Dunst K, Geltner C, Margreiter R. Evaluation of factors damaging the bronchial wall in lung transplantation. *J Heart Lung Transplant*. 2005;24:275–81.
160. Hyttinen TA, Heikkila LJ, Verkkala KA, Sipponen JT, Vainikka TL, Halme M, et al. Bronchial artery revascularization improves tracheal anastomotic healing after lung transplantation. *Scand Cardiovasc J*. 2000;34:213–8.
161. Shennib H, Massard G. Airway complications in lung transplantation. *Ann Thorac Surg*. 1994;57:506–11.
162. Kshettry VR, Kroshus TJ, Hertz MI, Hunter DW, Shumway SJ, Bolman SRM. Early and late airway complications after lung transplantation: incidence and management. *Ann Thorac Surg*. 1997;63:1576–83.
163. Erasmus D, Keller C, Alvarez F. Large airway complications in 150 consecutive lung transplant recipients. *Journal of Bronchology*. 2008;15:152–7.

164. Moreno P, Alvarez A, Algar FJ, Cano JR, Espinosa D, Cerezo F, et al. Incidence, management and clinical outcomes of patients with airway complications following lung transplantation. *Eur J Cardiothoracic Surg.* 2008;34: 1198–205.
165. Fernández-Bussy S, Majid A, Caviedes I, Akindipe O, Baz M, Jantz M. Treatment of airway complications following lung transplantation. *Arch Bronconeumol.* 2011;47:128–33.
166. Fernández-Bussy S. Clinical experience with a new removable tracheobronchial stent in the management of airway complications after lung transplantation. *J Heart Lung Transplant.* 2009;28:683–8.
167. De Gracia J, Culebras M, Álvarez A, Catalán E, de la Rosa D, Maestre J. Bronchoscopic balloon dilatation in the management of bronchial stenosis following lung transplantation. *Respir Med.* 2007;101:27–33.
168. Dutau H, Cavailles A, Sakr L, Badier M, Gaubert JY, Boniface S, et al. A retrospective study of silicone stent placement for management of anastomotic airway complications in lung transplant recipients: short- and long-term outcomes. *J Heart Lung Transplant.* 2010;29:658–64.
169. Lari SM, Gonin F, Colchen A. The management of bronchus intermedius complications after lung transplantation: a retrospective study. *J Cardiothorac Surg.* 2012;7:8.